NewEdge Advisors LLC Acquires 13,159 Shares of DexCom, Inc. (NASDAQ:DXCM)

NewEdge Advisors LLC lifted its position in shares of DexCom, Inc. (NASDAQ:DXCM - Free Report) by 122.5% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 23,905 shares of the medical device company's stock after purchasing an additional 13,159 shares during the period. NewEdge Advisors LLC's holdings in DexCom were worth $1,859,000 as of its most recent SEC filing.

Other institutional investors have also recently added to or reduced their stakes in the company. Forvis Mazars Wealth Advisors LLC increased its stake in shares of DexCom by 0.7% in the 4th quarter. Forvis Mazars Wealth Advisors LLC now owns 17,481 shares of the medical device company's stock valued at $1,359,000 after buying an additional 118 shares during the period. Principal Securities Inc. grew its stake in shares of DexCom by 3.4% during the fourth quarter. Principal Securities Inc. now owns 4,069 shares of the medical device company's stock worth $316,000 after purchasing an additional 135 shares during the period. Larson Financial Group LLC lifted its holdings in DexCom by 40.5% during the fourth quarter. Larson Financial Group LLC now owns 475 shares of the medical device company's stock worth $37,000 after acquiring an additional 137 shares in the last quarter. Level Four Advisory Services LLC lifted its holdings in DexCom by 1.1% during the fourth quarter. Level Four Advisory Services LLC now owns 13,196 shares of the medical device company's stock worth $1,026,000 after acquiring an additional 150 shares in the last quarter. Finally, Covestor Ltd grew its stake in shares of DexCom by 15.6% during the 4th quarter. Covestor Ltd now owns 1,109 shares of the medical device company's stock worth $86,000 after acquiring an additional 150 shares in the last quarter. 97.75% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In other news, COO Jacob Steven Leach sold 2,634 shares of the firm's stock in a transaction on Wednesday, January 29th. The stock was sold at an average price of $86.91, for a total transaction of $228,920.94. Following the completion of the transaction, the chief operating officer now directly owns 268,644 shares in the company, valued at $23,347,850.04. This trade represents a 0.97 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Jereme M. Sylvain sold 2,090 shares of the firm's stock in a transaction on Wednesday, January 29th. The shares were sold at an average price of $86.91, for a total value of $181,641.90. Following the transaction, the executive vice president now owns 83,526 shares of the company's stock, valued at $7,259,244.66. The trade was a 2.44 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 105,009 shares of company stock worth $8,044,178 over the last three months. 0.32% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

DXCM has been the subject of several research reports. Cfra Research raised DexCom to a "hold" rating in a report on Friday, March 21st. Canaccord Genuity Group raised their price target on shares of DexCom from $99.00 to $103.00 and gave the company a "buy" rating in a research note on Friday, February 14th. Mizuho began coverage on shares of DexCom in a research note on Thursday, April 10th. They set an "outperform" rating and a $85.00 target price for the company. Baird R W raised shares of DexCom from a "hold" rating to a "strong-buy" rating in a research note on Thursday, January 16th. Finally, Morgan Stanley lifted their price objective on shares of DexCom from $75.00 to $82.00 and gave the company an "equal weight" rating in a report on Friday, February 14th. Five equities research analysts have rated the stock with a hold rating, thirteen have issued a buy rating and three have assigned a strong buy rating to the company's stock. According to MarketBeat, DexCom currently has a consensus rating of "Moderate Buy" and a consensus target price of $99.00.

DexCom Stock Down 0.7 %

Shares of DXCM stock traded down $0.48 during midday trading on Monday, reaching $71.18. 2,782,702 shares of the stock were exchanged, compared to its average volume of 4,213,899. DexCom, Inc. has a 1 year low of $57.52 and a 1 year high of $132.26. The company's 50 day moving average is $72.72 and its two-hundred day moving average is $76.74. The company has a current ratio of 1.47, a quick ratio of 1.28 and a debt-to-equity ratio of 0.59. The firm has a market cap of $27.91 billion, a PE ratio of 49.78, a price-to-earnings-growth ratio of 2.30 and a beta of 1.50.

DexCom (NASDAQ:DXCM - Get Free Report) last posted its earnings results on Thursday, February 13th. The medical device company reported $0.45 earnings per share for the quarter, missing analysts' consensus estimates of $0.50 by ($0.05). DexCom had a return on equity of 30.14% and a net margin of 14.29%. On average, equities research analysts predict that DexCom, Inc. will post 2.03 EPS for the current year.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.